Edith Michelle Marom
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Edith Michelle Marom has a total of 31 co-authors. Here are the top co-authors by number of shared publications:
- Maximiliano Klug
Division of Diagnostic Imaging, Sheba Medical Center, Tel Hashomer, 2 Derech Sheba St, Ramat Gan 5265601, Israel
6 shared publications - Zehavit Kirshenboim
Division of Diagnostic Imaging, Sheba Medical Center, Tel Hashomer, 2 Derech Sheba St, Ramat Gan 5265601, Israel
5 shared publications - Chad D. Strange
From the Department of Thoracic Imaging, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Blvd, Unit 1478, Houston, TX 77030
4 shared publications - Mylene T. Truong
Department of Thoracic Imaging, M D Anderson Cancer Center, University of Texas, Houston, TX 77030, USA
4 shared publications Efrat Ofek
3 shared publicationsEli Konen
Division of Diagnostic Imaging, The Chaim Sheba Medical Center, Tel Hashomer, 2 Derech Sheba St, Ramat Gan 5265601, Israel
3 shared publications
Latest Publications
- 1 October 2025
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 7 (5) , e250144
The Ninth Edition TNM Staging System for Thymic Epithelial Tumors: A Comprehensive Review
The ninth edition of the TNM classification for thymic epithelial tumors, effective January 2025, introduces updated criteria for tumor extent, lymph node involvement, and metastasis, reinforcing the critical role of imaging in accurate staging and treatment planning.
- 1 October 2025
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 7 (5) , e250144
The Ninth Edition TNM Staging System for Thymic Epithelial Tumors: A Comprehensive Review
The ninth edition of the TNM classification for thymic epithelial tumors, effective January 2025, introduces updated criteria for tumor extent, lymph node involvement, and metastasis, reinforcing the critical role of imaging in accurate staging and treatment planning.
- 1 April 2025
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 7 (2) , e240189
Denoised Ultra-Low-Dose Chest CT to Assess Pneumonia in Individuals Who Are Immunocompromised
Denoised ultra-low-dose CT correctly identified pneumonia and features associated with invasive fungal pneumonia in individuals who were immunocompromised while substantially reducing radiation dose.
- 1 April 2025
- Published by Radiological Society of North America (RSNA) in Radiology: Cardiothoracic Imaging
- Vol. 7 (2) , e240189
Denoised Ultra-Low-Dose Chest CT to Assess Pneumonia in Individuals Who Are Immunocompromised
Denoised ultra-low-dose CT correctly identified pneumonia and features associated with invasive fungal pneumonia in individuals who were immunocompromised while substantially reducing radiation dose.
- 1 December 2024
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 44 (12) , e240057
Proposed Ninth Edition TNM Staging System for Lung Cancer: Guide for Radiologists
A comprehensive understanding of the proposed updates in the ninth edition of the TNM staging system for lung cancer enables radiologists to provide accurate clinical radiologic staging, enhancing precision in predicting therapy outcomes and facilitating an individualized approach for each patient.
- 1 December 2024
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 44 (12) , e240057
Proposed Ninth Edition TNM Staging System for Lung Cancer: Guide for Radiologists
A comprehensive understanding of the proposed updates in the ninth edition of the TNM staging system for lung cancer enables radiologists to provide accurate clinical radiologic staging, enhancing precision in predicting therapy outcomes and facilitating an individualized approach for each patient.
- 1 September 2024
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 44 (9) , e240196
RadioGraphics Update: The Ninth Edition TNM Staging System for Thymic Epithelial Tumors
Editor's Note.-RadioGraphics Update articles supplement or update information found in full-length articles previously published in RadioGraphics. These updates, written by at least one author of the previous article, provide a brief synopsis that emphasizes important new information such as technological advances, revised imaging protocols, new clinical guidelines involving imaging, or updated classification schemes.
- 1 September 2024
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 44 (9) , e240196
RadioGraphics Update: The Ninth Edition TNM Staging System for Thymic Epithelial Tumors
Editor's Note.-RadioGraphics Update articles supplement or update information found in full-length articles previously published in RadioGraphics. These updates, written by at least one author of the previous article, provide a brief synopsis that emphasizes important new information such as technological advances, revised imaging protocols, new clinical guidelines involving imaging, or updated classification schemes.
- 1 May 2024
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 44 (5) , e230091
Thymic Imaging Pitfalls and Strategies for Optimized Diagnosis
Understanding the advantages and limitations of each thymic imaging modality enables radiologists to select the correct imaging technique, improve the quality of image acquisition and measurements,... Thymic imaging is challenging because the imaging appearance of a variety of benign and malignant thymic conditions are similar. CT is the most commonly used modality for mediastinal imaging, while...
- 1 May 2024
- Published by Radiological Society of North America (RSNA) in RadioGraphics
- Vol. 44 (5) , e230091
Thymic Imaging Pitfalls and Strategies for Optimized Diagnosis
Understanding the advantages and limitations of each thymic imaging modality enables radiologists to select the correct imaging technique, improve the quality of image acquisition and measurements,... Thymic imaging is challenging because the imaging appearance of a variety of benign and malignant thymic conditions are similar. CT is the most commonly used modality for mediastinal imaging, while...
- 1 July 2022
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 4 (4) , e220033
Ulcerative Colitis Exacerbation after Rituximab Treatment in Posttransplant Lymphoproliferative Disease
- 1 July 2022
- Published by Radiological Society of North America (RSNA) in Radiology: Imaging Cancer
- Vol. 4 (4) , e220033
Ulcerative Colitis Exacerbation after Rituximab Treatment in Posttransplant Lymphoproliferative Disease
- 13 April 2022
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 220, 106815
Weakly supervised attention model for RV strain classification from volumetric CTPA scans
- 13 April 2022
- Published by Elsevier in Computer Methods and Programs in Biomedicine
- Vol. 220, 106815
Weakly supervised attention model for RV strain classification from volumetric CTPA scans
- Open Access
- 1 December 2021
- Published by AME Publishing Company in Mediastinum
- Vol. 5, AB003
AB003. Circulating EBV (cEBV) and metabolic imaging monitoring during therapy for thymic lymphoepithelioma-like carcinoma (tLELC): a case study
EBV association with the rare and usually fatal tLELC has been well documented, but not thoroughly studied, in the literature. A symptomatic 16-year-old boy was admitted for a locally advanced, inoperable EBV-associated tLELC. The diagnosis was established by appropriate immunohistology and RNA in-situ hybridization (ISH) for EBNA. The patient responded to induction combination chemotherapy followed by consolidation irradiation course given to the primary mediastinal lesion. Later, upon disease progression, he was enrolled to an immunotherapy (pembrolizumab) phase II clinical trial. Under this therapy, disease control was regained and lasted about 8 months. Treatment was discontinued, due to disease progression, after completion of 13 courses. Disease evaluation included serial circulating plasma EBV titer as well as concomitant 18F-FDG PET-CT scintigraphy/scanning. We attempt herein to compare how well the four different measurement modalities employed, namely-RECIST 1.1., active FDG-avid tumor volume, SUVmax and cEBV reflect the clinical course of disease and tumor burden changes. Among these, FDG-avid tumor volume apparently conforms better than conventional bi-dimentional CT-based RECIST 1.1 to the actual tumor burden and clinical course. Similarly, cEBV titer seems sensitive to various therapeutic intervention including irradiation. Furthermore, being a subclinical sensor, it could provide lead-time and herald overt disease progression. Albeit the entity presented, namely EBV-associated tLELC is extremely rare, certain conclusions obtained could, when properly modified, be applied in the management of more common conditions.
- 1 December 2021
- Published by AME Publishing Company in Mediastinum
- Vol. 5, AB003
Open AccessAB003. Circulating EBV (cEBV) and metabolic imaging monitoring during therapy for thymic lymphoepithelioma-like carcinoma (tLELC): a case study
EBV association with the rare and usually fatal tLELC has been well documented, but not thoroughly studied, in the literature. A symptomatic 16-year-old boy was admitted for a locally advanced, inoperable EBV-associated tLELC. The diagnosis was established by appropriate immunohistology and RNA in-situ hybridization (ISH) for EBNA. The patient responded to induction combination chemotherapy followed by consolidation irradiation course given to the primary mediastinal lesion. Later, upon disease progression, he was enrolled to an immunotherapy (pembrolizumab) phase II clinical trial. Under this therapy, disease control was regained and lasted about 8 months. Treatment was discontinued, due to disease progression, after completion of 13 courses. Disease evaluation included serial circulating plasma EBV titer as well as concomitant 18F-FDG PET-CT scintigraphy/scanning. We attempt herein to compare how well the four different measurement modalities employed, namely-RECIST 1.1., active FDG-avid tumor volume, SUVmax and cEBV reflect the clinical course of disease and tumor burden changes. Among these, FDG-avid tumor volume apparently conforms better than conventional bi-dimentional CT-based RECIST 1.1 to the actual tumor burden and clinical course. Similarly, cEBV titer seems sensitive to various therapeutic intervention including irradiation. Furthermore, being a subclinical sensor, it could provide lead-time and herald overt disease progression. Albeit the entity presented, namely EBV-associated tLELC is extremely rare, certain conclusions obtained could, when properly modified, be applied in the management of more common conditions.
- 1 March 2021
- Published by Elsevier in Radiologic Clinics of North America
- Vol. 59 (2) , 183-192
Thymic Epithelial Neoplasms
- 1 March 2021
- Published by Elsevier in Radiologic Clinics of North America
- Vol. 59 (2) , 183-192
Thymic Epithelial Neoplasms
- Open Access
- 1 July 2019
- Published by AME Publishing Company in Mediastinum
- Vol. 3, 29
Determining extent of invasion and follow-up of thymic epithelial malignancies
Thymic malignancies may exhibit aggressive behavior such as invasion of adjacent structures and involvement of the pleura and pericardium. The role of imaging in the evaluation of primary thymic neoplasms is to properly assess tumor staging, with emphasis on the detection of local invasion and distant spread of disease, correctly identifying candidates for preoperative neoadjuvant therapy. Different imaging modalities are used in the initial investigation of thymic malignancies including chest radiography, computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET), in particular with [18F] fluorodeoxyglucose (FDG). At this moment, CT is the most common imaging modality on the assessment of thymic malignancies. MRI has the benefit of no emission of damaging ionizing radiation reducing the radiation dose to the patient when compared with CT. For this reason, MRI has been playing an important role in the evaluation of tumor invasion and follow up imaging studies which becomes even more relevant in young patients or those patients with prior history of radiation therapy.
- 1 July 2019
- Published by AME Publishing Company in Mediastinum
- Vol. 3, 29
Open AccessDetermining extent of invasion and follow-up of thymic epithelial malignancies
Thymic malignancies may exhibit aggressive behavior such as invasion of adjacent structures and involvement of the pleura and pericardium. The role of imaging in the evaluation of primary thymic neoplasms is to properly assess tumor staging, with emphasis on the detection of local invasion and distant spread of disease, correctly identifying candidates for preoperative neoadjuvant therapy. Different imaging modalities are used in the initial investigation of thymic malignancies including chest radiography, computed tomography (CT), magnetic resonance imaging (MRI) and positron emission tomography (PET), in particular with [18F] fluorodeoxyglucose (FDG). At this moment, CT is the most common imaging modality on the assessment of thymic malignancies. MRI has the benefit of no emission of damaging ionizing radiation reducing the radiation dose to the patient when compared with CT. For this reason, MRI has been playing an important role in the evaluation of tumor invasion and follow up imaging studies which becomes even more relevant in young patients or those patients with prior history of radiation therapy.